tetano
Editor, Senior Moderator
Platelets
. 2020 Dec 3;1-8.
doi: 10.1080/09537104.2020.1852543. Online ahead of print.
Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure
Gianluca Campo[SUP] 1 2 [/SUP], Marco Contoli[SUP] 3 [/SUP], Alberto Fogagnolo[SUP] 4 [/SUP], Francesco Vieceli Dalla Sega[SUP] 2 [/SUP], Ottavio Zucchetti[SUP] 1 [/SUP], Luca Ronzoni[SUP] 3 [/SUP], Marco Verri[SUP] 4 [/SUP], Francesca Fortini[SUP] 2 [/SUP], Rita Pavasini[SUP] 1 [/SUP], Luca Morandi[SUP] 3 [/SUP], Simone Biscaglia[SUP] 1 [/SUP], Luca Di Ienno[SUP] 1 [/SUP], Emanuele D'Aniello[SUP] 1 [/SUP], Marco Manfrini[SUP] 2 [/SUP], Roberto Zoppellari[SUP] 4 [/SUP], Paola Rizzo[SUP] 2 5 [/SUP], Roberto Ferrari[SUP] 1 2 [/SUP], Carlo Alberto Volta[SUP] 4 [/SUP], Alberto Papi[SUP] 3 [/SUP], Savino Spadaro[SUP] 4 [/SUP]
Affiliations
Abstract
The aim of this study (NCT04343053) is to investigate the relationship between platelet activation, myocardial injury, and mortality in patients affected by Coronavirus disease 2019 (COVID-19). Fifty-four patients with respiratory failure due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were enrolled as cases. Eleven patients with the same clinical presentation, but negative for SARS-CoV-2 infection, were included as controls. Blood samples were collected at three different time points (inclusion [T1], after 7 ? 2 days [T2] and 14 ? 2 days [T3]). Platelet aggregation by light transmittance aggregometry and the circulating levels of soluble CD40 ligand (sCD40L) and P-selectin were measured. Platelet biomarkers did not differ between cases and controls, except for sCD40L which was higher in COVID-19 patients (p = .003). In COVID-19 patients, P-selectin and sCD40L levels decreased from T1 to T3 and were higher in cases requiring admission to intensive care unit (p = .004 and p = .008, respectively). Patients with myocardial injury (37%), as well as those who died (30%), had higher values of all biomarkers of platelet activation (p < .05 for all). Myocardial injury was an independent predictor of mortality. In COVID-19 patients admitted to hospital for respiratory failure, heightened platelet activation is associated with severity of illness, myocardial injury, and mortality. ClinicalTrials.gov number: NCT04343053.
Keywords: COVID-19; P-selectin; myocardial injury; platelet aggregation; soluble CD40 ligand.
. 2020 Dec 3;1-8.
doi: 10.1080/09537104.2020.1852543. Online ahead of print.
Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure
Gianluca Campo[SUP] 1 2 [/SUP], Marco Contoli[SUP] 3 [/SUP], Alberto Fogagnolo[SUP] 4 [/SUP], Francesco Vieceli Dalla Sega[SUP] 2 [/SUP], Ottavio Zucchetti[SUP] 1 [/SUP], Luca Ronzoni[SUP] 3 [/SUP], Marco Verri[SUP] 4 [/SUP], Francesca Fortini[SUP] 2 [/SUP], Rita Pavasini[SUP] 1 [/SUP], Luca Morandi[SUP] 3 [/SUP], Simone Biscaglia[SUP] 1 [/SUP], Luca Di Ienno[SUP] 1 [/SUP], Emanuele D'Aniello[SUP] 1 [/SUP], Marco Manfrini[SUP] 2 [/SUP], Roberto Zoppellari[SUP] 4 [/SUP], Paola Rizzo[SUP] 2 5 [/SUP], Roberto Ferrari[SUP] 1 2 [/SUP], Carlo Alberto Volta[SUP] 4 [/SUP], Alberto Papi[SUP] 3 [/SUP], Savino Spadaro[SUP] 4 [/SUP]
Affiliations
- PMID: 33270471
- DOI: 10.1080/09537104.2020.1852543
Abstract
The aim of this study (NCT04343053) is to investigate the relationship between platelet activation, myocardial injury, and mortality in patients affected by Coronavirus disease 2019 (COVID-19). Fifty-four patients with respiratory failure due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were enrolled as cases. Eleven patients with the same clinical presentation, but negative for SARS-CoV-2 infection, were included as controls. Blood samples were collected at three different time points (inclusion [T1], after 7 ? 2 days [T2] and 14 ? 2 days [T3]). Platelet aggregation by light transmittance aggregometry and the circulating levels of soluble CD40 ligand (sCD40L) and P-selectin were measured. Platelet biomarkers did not differ between cases and controls, except for sCD40L which was higher in COVID-19 patients (p = .003). In COVID-19 patients, P-selectin and sCD40L levels decreased from T1 to T3 and were higher in cases requiring admission to intensive care unit (p = .004 and p = .008, respectively). Patients with myocardial injury (37%), as well as those who died (30%), had higher values of all biomarkers of platelet activation (p < .05 for all). Myocardial injury was an independent predictor of mortality. In COVID-19 patients admitted to hospital for respiratory failure, heightened platelet activation is associated with severity of illness, myocardial injury, and mortality. ClinicalTrials.gov number: NCT04343053.
Keywords: COVID-19; P-selectin; myocardial injury; platelet aggregation; soluble CD40 ligand.